Beta-Blocker Use Is Associated with Improved Outcomes in Adult Burn Patients

Journal of Trauma - Injury, Infection and Critical Care

Volumn 56, Issue 2, 2004, Pages 265-271

  Arbabi, Saman ^a,b   Ahrns, Karla S ^a   Wahl, Wendy L ^a   Hemmila, Mark R ^a   Wang, Stewart C ^a   Brandt, Mary Margaret ^a   Taheri, Paul A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Beta adrenergic receptors; Beta blockers; Burn; Healing; Injury; Outcomes

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BODY SURFACE; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIURETIC THERAPY; DRUG EFFECT; DRUG USE; FATALITY; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; TACHYCARDIA; WOUND HEALING;

EID: 1542376580     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000109859.91202.C8     Document Type: Article

References (27)

1. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996;335:1713-1720.
2. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia: McSPI Research Group. Anesthesiology. 1998;88:7-17.
3. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001;345:1223-1229.
4. Morio B, Irtun O, Herndon DN, Wolfe RR. Propranolol decreases splanchnic triacylglycerol storage in burn patients receiving a high-carbohydrate diet. Ann Surg. 2002;236:218-225.
5. Aarsland A, Chinkes D, Wolfe RR, et al. Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone: rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged. Ann Surg. 1996;223:777-789.
6. Louis SN, Jackman GP, Nero TL, et al. Role of beta-adrenergic receptor subtypes in lipolysis. Cardiovasc Drugs Ther. 2000;14:565-577.
7. Sheridan RL. A great constitutional disturbance. N Engl J Med. 2001;345:1271-1272.
8. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785-792.
9. Byrne TA, Morrissey TB, Gatzen C, et al. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg. 1993;218:400-418.
10. Hart DW, Wolf SE, Chinkes DL, et al. Beta-blockade and growth hormone after burn. Ann Surg. 2002;236:450-457.
11. Ramirez RJ, Wolf SE, Barrow RE, Herndon DN. Growth hormone treatment in pediatric burns: a safe therapeutic approach. Ann Surg. 1998;228:439-448.
12. Hollyoak MA, Muller MJ, Meyers NA, et al. Beneficial wound healing and metabolic effects of clenbuterol in burned and nonburned rats. J Burn Care Rehabil. 1995;16(3 pt 1):233-240.
13. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension: IV - effect on plasma glucose and glucose tolerance. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Hypertension. 1985;7(6 pt 1):1008-1016.
14. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med. 2001;135:1079-1083.
15. Gore DC, Chinkes DL, Hart DW, et al. Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med. 2002;30:2438-2442.
16. Gore DC, Honeycutt D, Jahoor F, et al. Propranolol diminishes extremity blood flow in burned patients. Ann Surg. 1991;213:568-574.
17. Herndon DN, Barrow RE, Rutan TC, et al. Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients. Ann Surg. 1988;208:484-492.
18. Elenkov IJ, Hasko G, Kovacs KJ, Vizi ES. Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. J Neuroimmunol. 1995;61:123-131.
19. Fukuzawa M, Satoh J, Ohta S, et al. Modulation of tumor necrosis factor-alpha production with anti-hypertensive drugs. Immunopharmacology. 2000;48:65-74.
20. van der Poll T, Jansen J, Endert E, et al. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect Immun. 1994;62:2046-2050.
21. Remick DG. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des. 2003;9:75-82.
22. Remick DG, Bolgos GR, Siddiqui J, et al. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock. 2002;17:463-467.
23. Dowlati A, Levitan N, Remick SC. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med. 1999;134:405-409.
24. Schedlowski M, Hosch W, Oberbeck R, et al. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol. 1996;156:93-99.
25. Oberbeck R, van Griensven M, Nickel E, et al. Influence of beta-adrenoceptor antagonists on hemorrhage-induced cellular immune suppression. Shock. 2002;18:331-335.
26. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
27. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.